European Journal of Cancer
Volume 39, Issue 13 , Pages 1816-1817, September 2003

Rationale for drug combinations

  • J.F. Smyth

      Affiliations

    • Corresponding Author InformationTel.: +44-131-332-2471; fax: +44-131-332-8494

University of Edinburgh, Cancer Research Centre, Edinburgh, UK

Received 8 May 2003; accepted 8 May 2003.

No abstract is available. To read the body of this article, please view the Full Text online.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0959-8049(03)00452-0

doi:10.1016/S0959-8049(03)00452-0

European Journal of Cancer
Volume 39, Issue 13 , Pages 1816-1817, September 2003

Article Tools